Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC (NeoASPECT)

NCT07743632 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT07743632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC (NeoASPECT)
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2033
Enrollment
110 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer